Venture capital financings for biopharmaceutical companies could end 2012 with a strong showing at the pace that new and early-stage firms are announcing new funding rounds, including at least three deals above $10 million kicking off the last full work week before Christmas and New Year's celebrations.
Oncology-focused Blend Therapeutics in Watertown, Massachusetts and Evanston, Illinois-based Naurex with interests in psychiatry and neurology announced Series B rounds totaling $16 million and $38 million, respectively. Allakos in San...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?